A multinational, open-label, dose escalation Phase I/II study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types

×

Message d'erreur

  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 53 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 95 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
A multinational, open-label, dose escalation Phase I/II study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types
Date receipt dossier: 
25 oct 2016
EudraCT number: 
2016-003312-12
Company / Sponsor: 
Celyad
Phase: 
I
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
cancer
Therapeutic approach: 
Immunotherapy
Genetic modification: 
NKG2D-chimeric antigen receptor
Method of transfer of nucleic acid of interest: 
Moloney Murine Leukemia Virus
Administered biological material: 
Autologous T-cells retrovirally transduced with a chimeric antigen receptor based on the NKG2D receptor
Route of administration: 
Intravenous
Locations in Belgium: 
UZ Gent, Grand Hôpital de Charleroi
Nr of subjects: 
24 participants
Foreseen duration: 
4 years
Type of procedure: 
Contained use only
Current status: 
Authorized